Snowflake (SNOW) and CareDx (CDNA) climbed to fresh 52-week highs on Monday, with BTIG highlighting Snowflake’s AI-driven product momentum and Craig-Hallum upgrading CareDx after the company raised its full-year 2026 guidance.At the time of writing, CDNA stock was up around 10% after hitting an int…
CareDx (CDNA) raised FY2026 revenue guide to $490–$500M. Q2 revenue surged 52% to $131.9M; net income $110.6M, adj. EPS $0.37. Stock jumped ~16% to $44.14.CareDx (CDNA) granted 15,
CareDx, Inc. (Nasdaq: CDNA) — a leading precision medicine diagnostics company in transplant, specialty oncology, and cell therapy, today announced that, on July 30, 2026, CareDx granted to James McNally, the Company’s newly appointed Executive Advisor, certain stock awards as an inducement materia…
Revenue grew 52% year-over-year to $132M, driven by strong transplant and specialty oncology testing. Guidance was raised for 2026, with revenue expected to reach $490–$500M and adjusted EBITDA margin at 15%. Integration of NavDx and favorable Medicare policy support future growth.Based on CareDx…
Revenue surged 52% year-over-year to $132 million in Q2 2026, with net income of $111 million driven by a $113 million gain from the lab products business sale. Testing services and digital solutions saw robust growth, and the company completed the acquisition of Naveris while maintaining a strong…
CareDx CDNA recently completed the acquisition of Naveris, expanding its presence in high-growth specialty oncology. The company had announced the acquisition agreement in April as part of its strategy to strengthen its U.S. Precision Medicine Testing Services and Patient and Digital Solutions.The…
(20:05 GMT) *CareDx Completes Acquisition Of Naveris, Extending Leadership Into High-Growth Specialty Oncology >CDNA (20:05 GMT) Press Release: CareDx Completes Acquisition of Naveris, Extending Leadership into High-Growth Specialty OncologyNavDx(R) is the only Medicare-covered MRD test for HPV-pos…
CareDx Completes Acquisition Of Naveris, Extending Leadership Into High-Growth Specialty Oncology >CDNA
EUROBIO SCIENTIFIC FINALIZES THE ACQUISITION OF CAREDX’s TRANSPLANT LAB PRODUCT DIVISIONParis, July 1st, 2026 ,8 AM CETEurobio Scientific (FR0013240934, ALERS, PEA-PME eligible), a leading French group in in-vitro diagnostics for transplantation, oncology and infectious diseases, today announces th…
